Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- products for treating diabetes and obesity (84.3%);
- hemophilia treatment products (8.4%): mainly injections of protein;
- growth hormones (6%): used for treatment of growth deficiencies in children;
- hormone replacement products (1.3%): used for treatment of the menopause and prevention of osteoporosis.
Net sales are distributed geographically as follows: Europe (19.1%), the United States (47.1%), North America (2.5%), Africa/Asia/Middle East/Oceania (11.5%), China (10.5%), Japan and Korea (5.3%) and Latin America (4%).
Number of employees : 45 323 people.
2019 2020 Delta DKK (in Million) % DKK (in Million) % Diabetes and Obesity Care 102,840 84.3% 108,020 85.1% +5.04% Biopharm 19,181 15.7% 18,926 14.9% -1.33%
2020 DKK (in Million) % United States 57,824 45.6% EMEA 34,297 27% Rest of the World 17,448 13.7% China 14,084 11.1% Canada 3,293 2.6%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
10
537,000,000
0
0.0% 0
0.0% 69.8%
Stock B
1
1,772,564,000
1,612,733,341
91.0% 37,500,000
2.1%
Shareholders Novo Nordisk A/S (DK0060534915) Novo Nordisk A/S (US)
Name Equities % Novo Holdings A/S (Investment Company) 116,129,000
6.55% Norges Bank Investment Management 43,498,435
2.45% The Vanguard Group, Inc. 40,178,414
2.27% Alecta Pension Insurance Mutual 27,085,444
1.53% BlackRock Fund Advisors 26,690,203
1.51% Fundsmith LLP 20,525,100
1.16% BlackRock Investment Management (UK) Ltd. 18,388,805
1.04% Capital Research & Management Co. (World Investors) 16,895,809
0.95% Handelsbanken Fonder AB 15,721,299
0.89% Flossbach von Storch AG 13,895,000
0.78%
Name Equities % Renaissance Technologies LLC 24,846,671
1.40% Fisher Asset Management LLC 16,054,695
0.91% United States Trust Co., NA 13,127,240
0.74% Loomis, Sayles & Co. LP 6,675,375
0.38% Jackson Square Partners LLC 6,639,477
0.37% Capital Research & Management Co. (International Investors) 5,072,371
0.29% Fayez Sarofim & Co. 4,965,355
0.28% Cambiar Investors LLC 4,608,255
0.26% Managed Account Advisors LLC 4,457,617
0.25% Folketrygdfondet 4,249,410
0.24%
Name Equities % Valuation
Novo Nordisk A/S (NOVO B) 12,620,192 0.71% 931,300,254 USD NNIT A/S (NNIT) 4,375,000 17.5% 77,105,088 USD Innate Pharma (IPH) 9,817,546 12.4% 42,073,388 USD
-
- Main Market Large
- OMXC 20 / Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, PEA, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
- Bloomberg Code :
NOVOB:DC
- Reuters Code :
NOVOb.CO
- Datastream Code :
DK:NON
Company contact information
BP shareholder vote shows increased support for tougher climate targets
NOVO NORDISK AS
Sector Other Pharmaceuticals
Connections : Novo Nordisk A/S
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
